Econazole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Econazole: From Superficial Antifungal to Majocchi Granuloma
One-Sentence Summary
Econazole is a broad-spectrum imidazole antifungal agent used globally for superficial dermatomycoses and cutaneous candidiasis, but currently holds no marketing authorization in Singapore. The TxGNN model predicts it may be effective for Majocchi Granuloma, with 0 clinical trials and 0 publications directly supporting this specific indication. Across the full top-10 prediction set, notably stronger evidence exists for related fungal indications: vulvovaginal candidiasis (rank 7, L2) is supported by at least 5 direct RCTs featuring econazole, and superficial mycosis (rank 4, L3) carries 19 supporting publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in Singapore; globally established for superficial dermatomycoses and cutaneous candidiasis |
| Predicted New Indication | Majocchi Granuloma |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only; no direct clinical studies identified) |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known information, Econazole is an imidazole-class antifungal that inhibits CYP51 (lanosterol 14α-demethylase), blocking ergosterol biosynthesis and disrupting fungal membrane integrity. Its broad-spectrum fungistatic and fungicidal activity against dermatophytes (Trichophyton, Microsporum, Epidermophyton), yeasts (Candida spp.), and dimorphic fungi has been established in both in vitro and clinical settings over decades.
Majocchi granuloma is a rare deep dermatophyte infection — predominantly caused by Trichophyton rubrum — in which organisms invade the hair follicle below the infundibulum and into the deep dermis and subcutis, provoking a perifollicular granulomatous response. Because econazole's CYP51 inhibition mechanism is directly active against T. rubrum, the mechanistic link to Majocchi granuloma is biologically sound.
The critical constraint, however, is tissue penetration. Majocchi granuloma lesions are located in the deep dermis — well beyond the reach of conventional topical econazole preparations. Clinical guidelines consistently require systemic antifungals (oral terbinafine or itraconazole) for this condition; topical imidazoles are regarded as insufficient as monotherapy. The high TxGNN score likely reflects the tight mechanistic alignment between econazole and dermatophyte biology at a knowledge-graph level, rather than a currently actionable clinical opportunity with available formulations.
Clinical Trial Evidence
Currently no related clinical trials registered for Econazole in Majocchi Granuloma.
Literature Evidence
Currently no related literature available for Econazole in Majocchi Granuloma.
Singapore Market Information
Econazole is currently not registered in Singapore. No product authorizations are on record (total licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trial or published literature evidence supports econazole for Majocchi granuloma, and the route-of-administration mismatch — topical formulation versus a deep tissue infection requiring systemic penetration — makes this prediction clinically impractical with existing dosage forms.
To proceed, the following is needed:
- MOA and susceptibility data: Confirm econazole's CYP51 inhibition profile and minimum inhibitory concentration (MIC) data against T. rubrum to formally characterize the mechanistic link
- Novel formulation research: Evaluate whether nanoparticle-based or lipid-carrier econazole delivery systems (see PMID 26883854 on imprinted textile delivery) could achieve therapeutic concentrations in deep dermal tissue
- Case reports or observational data: Identify any case series where econazole was used adjunctively in Majocchi granuloma, including combination with systemic therapy
- Safety profile retrieval: Obtain full prescribing information (warnings, contraindications, DDIs) from a reference market where econazole is licensed, to complete the S1 safety assessment
- Consider prioritizing a higher-evidence indication: Within this Evidence Pack, vulvovaginal candidiasis (rank 7, L2 evidence, ≥5 direct econazole RCTs dating from 1976–2011, recommendation: Proceed with Guardrails) and vulvovaginitis (rank 8, L2, similar RCT base) represent significantly more actionable repurposing candidates for Singapore regulatory evaluation — both have direct econazole clinical data and an established formulation route (vaginal pessary/cream)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.